Influence of the tumor microenvironment on angiogenesis

Future Oncology

Volumn 7, Issue 3, 2011, Pages 395-408

  Payne, Sarah J L ^a   Jones, Louise ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

angiogenesis; extracellular matrix; fibroblast; microenvironment; stroma

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOPOIETIN 1; ANGIOPOIETIN RECEPTOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CATHEPSIN; CHEMOKINE RECEPTOR CXCR4; CILENGITIDE; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 2; GLYCOSAMINOGLYCAN; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; NONSTEROID ANTIINFLAMMATORY AGENT; PLASMIN; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN SYNTHASE INHIBITOR; STROMAL CELL DERIVED FACTOR 1ALPHA; THROMBIN; THROMBOPLASTIN; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; UROKINASE; VASCULOTROPIN A;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BASEMENT MEMBRANE; CANCER CELL; CANCER GROWTH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG TARGETING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION; GLIOMA; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; LYMPHOCYTE; MAST CELL; MOLECULAR INTERACTION; MYOFIBROBLAST; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PERICYTE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; QUALITY OF LIFE; REVIEW; SMOOTH MUSCLE FIBER; STROMA; STROMA CELL; TH1 CELL; TH2 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ANGIOGENESIS MODULATING AGENTS; ANIMALS; ANOXIA; EXTRACELLULAR MATRIX; HUMANS; INFLAMMATION; MACROPHAGES; MONOCYTES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEUTROPHILS; PROGNOSIS; TUMOR MICROENVIRONMENT;

EID: 79953154623     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.13     Document Type: Review

References (167)

1. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW: The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 70(9-10), 537-546 (2002). (Pubitemid 36194318)
2. Coussens LM, Werb Z: Inflammation and cancer. Nature 420(6917), 860-867 (2002). (Pubitemid 36019639)
3. Kumar V: Tissue repair: cellular growth, fibrosis, and wound healing. In: Robbins and Cotran Pathologic Basis of Disease (7th Edition). Saunders, PA, USA (2004).
4. Brown LF, Guidi AJ, Schnitt SJ, et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin. Cancer Res. 5(5), 1041-1056 (1999). (Pubitemid 29233218)
5. Vleugel MM, Bos R, van der Groep P, et al. Lack of lymphangiogenesis during breast carcinogenesis. J. Clin. Pathol. 57(7), 746-751 (2004). (Pubitemid 38901491)
6. Toi M, Inada K, Suzuki H, Tominaga T: Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res. Treat. 36(2), 193-204 (1995).
7. Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J. Natl Cancer Inst. 89(2), 139-147 (1997). (Pubitemid 27034790)
8. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med. 324(1), 1-8 (1991).
9. Teo NB, Shoker BS, Jarvis C, Martin L, Sloane JP, Holcombe C: Angiogenesis and invasive recurrence in ductal carcinoma in situ of the breast. Eur. J. Cancer 39(1), 38-44 (2003). (Pubitemid 36005423)
10. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3), 353-364 (1996). (Pubitemid 26272076)
11. Rundhaug JE: Matrix metalloproteinases and angiogenesis. J. Cell Mol. Med. 9(2), 267-285 (2005).
12. Papetti M, Herman IM: Mechanisms of normal and tumor-derived angiogenesis. Am. J. Physiol. Cell Physiol. 282(5), C947-C970 (2002). (Pubitemid 34663101)
13. Risau W: Mechanisms of angiogenesis. Nature 386(6626), 671-674 (1997). (Pubitemid 27193480)
14. Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C: Role of PDGF-B and PDGFR-b in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126(14), 3047-3055 (1999). (Pubitemid 29378170)
15. Carmeliet P: Angiogenesis in health and disease. Nat. Med. 9(6), 653-660 (2003). (Pubitemid 36749213)
16. Folkman J: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182-1186 (1971).
17. Bolontrade MF, Zhou RR, Kleinerman ES: Vasculogenesis plays a role in the growth of Ewing's sarcoma in vivo. Clin. Cancer Res. 8(11), 3622-3627 (2002). (Pubitemid 35340741)
18. De Palma M, Venneri MA, Galli R, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8(3), 211-226 (2005). (Pubitemid 41317592)
19. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155(3), 739-752 (1999). (Pubitemid 29426820)
20. Rice A, Quinn CM: Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast. J. Clin. Pathol. 55(8), 569-574 (2002).
21. Kerbel RS, Viloria-Petit A, Okada F, Rak J: Establishing a link between oncogenes and tumor angiogenesis. Mol. Med. 4(5), 286-295 (1998). (Pubitemid 28361654)
22. Rak J, Mitsuhashi Y, Sheehan C, et al. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res. 60(2), 490-498 (2000). (Pubitemid 30070780)
23. Pal S, Claffey KP, Dvorak HF, Mukhopadhyay D: The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J. Biol. Chem. 272(44), 27509-27512 (1997). (Pubitemid 27473535)
24. Bouvet M, Ellis LM, Nishizaki M, et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res. 58(11), 2288-2292 (1998). (Pubitemid 28252680)
25. Folkman J, Shing Y: Angiogenesis. J. Biol. Chem. 267(16), 10931-10934 (1992).
26. Plank MJ, Sleeman BD: A reinforced random walk model of tumour angiogenesis and anti-angiogenic strategies. Math. Med. Biol. 20(2), 135-181 (2003). (Pubitemid 37526839)
27. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 407(6801), 249-257 (2000).
28. Ferrara N, Henzel WJ: Pituitary follicular cells secrete a novel heparin in binding growth factors specific for vascular endothelial cells. Biochem. Biophys. Res. Comm. 161(2), 851-858 (1989). (Pubitemid 19162712)
29. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219(4587), 983-985 (1983).
30. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246(4935), 1309-1312 (1989). (Pubitemid 20066717)
31. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246(4935), 1306-1309 (1989). (Pubitemid 20066716)
32. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25(4), 581-611 (2004). (Pubitemid 39099316)
33. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23(5), 1011-1027 (2005). (Pubitemid 46202320)
34. Kawasaki T, Kitsukawa T, Bekku Y, et al. A requirement for neuropilin-1 in embryonic vessel formation. Development 126(21), 4895-4902 (1999).
35. Van Hoef ME, Knox WF, Dhesi SS, Howell A, Schor AM: Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur. J. Cancer 29A(8), 1141-1145 (1993). (Pubitemid 23156639)
36. Hall NR, Fish DE, Hunt N, Goldin RD, Guillou PJ, Monson JR: Is the relationship between angiogenesis and metastasis in breast cancer real? Surg. Oncol. 1(3), 223-229 (1992).
37. Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur. J. Cancer 38(12), 1564-1579 (2002). (Pubitemid 34876495)
38. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med. 124(7), 966-978 (2000).
39. Brown LF, Berse B, Jakman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol. 26(1), 86-91 (1995).
40. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor b-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57(5), 963-969 (1997). (Pubitemid 27098025)
41. Toi M, Kondo S, Suzuki H, et al. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 77(6), 1101-1106 (1996). (Pubitemid 26080900)
42. Lantzsch T, Hefler L, Krause U, et al. The correlation between immunohistochemically-detected markers of angiogenesis and serum vascular endothelial growth factor in patients with breast cancer. Anticancer Res. 22(3), 1925-1928 (2002). (Pubitemid 34839222)
43. Valkovic T, Dobrila F, Melato M, Sasso F, Rizzardi C, Jonjic N: Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma. Virchows Arch. 440(6), 583-588 (2002). (Pubitemid 34809688)
44. Guidi AJ, Schnitt SJ, Fischer L, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 80(10), 1945-1953 (1997). (Pubitemid 27479789)
45. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14(5), 518-527 (2008). (Pubitemid 351655218)
46. Mustafa DA, Burgers PC, Dekker LJ, et al. Identification of glioma neovascularization-related proteins by using MALDI-FTMS and nano-LC fractionation to microdissected tumor vessels. Mol. Cell. Proteomics 6(7), 1147-1157 (2007). (Pubitemid 47099226)
47. Bruneel A, Labas V, Mailloux A, et al. Proteomic study of human umbilical vein endothelial cells in culture. Proteomics 3(5), 714-723 (2003). (Pubitemid 36570261)
48. Staton CA, Reed MW, Brown NJ: A critical analysis of current in vitro and in vivo angiogenesis assays. Int. J. Exp. Pathol. 90(3), 195-221 (2009).
49. Jackson CJ, Nguyen M: Human microvascular endothelial cells differ from macrovascular endothelial cells in their expression of matrix metalloproteinases. Int. J. Biochem. Cell Biol. 29(10), 1167-1177 (1997). (Pubitemid 27522556)
50. Aird WC: Endothelial cell heterogeneity. Crit. Care Med. 31(Suppl. 4), S221-S230 (2003). (Pubitemid 36458171)
51. Nisato RE, Harrison JA, Buser R, et al. Generation and characterization of telomerase-transfected human lymphatic endothelial cells with an extended life span. Am. J. Pathol. 165(1), 11-24 (2004). (Pubitemid 38821810)
52. Stribbling SM, Friedlos F, Martin J, et al. Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect. Hum. Gene Ther. 11(2), 285-292 (2000). (Pubitemid 30080386)
53. Brown NJ, Staton CA, Rodgers GR, Corke KP, Underwood JC, Lewis CE: Fibrinogen E fragment selectively disrupts the vasculature and inhibits the growth of tumours in a syngeneic murine model. Br. J. Cancer 86(11), 1813-1816 (2002). (Pubitemid 34712928)
54. Staton CA, Stribbling SM, Tazzyman S, Hughes R, Brown NJ, Lewis CE: Current methods for assaying angiogenesis in vitro and in vivo. Int. J. Exp. Pathol. 85(5), 233-248 (2004). (Pubitemid 39319155)
55. Poon RT, Fan ST, Wong J: Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 19(4), 1207-1225 (2001). (Pubitemid 32176299)
56. Bertolini F, Shaked Y, Mancuso P, Kerbel RS: The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer 6(11), 835-845 (2006). (Pubitemid 44629895)
57. Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a Phase I trial in rectal cancer patients. J. Clin. Oncol. 23(31), 8136-8139 (2005). (Pubitemid 46657433)
58. Beaudry P, Force J, Naumov GN, et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors an- mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin. Cancer Res. 11(9), 3514-3522 (2005).
59. Sessa C, Guibal A, Del Conte G, Ruegg C: Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat. Clin. Pract. Oncol. 5(7), 378-391 (2008). (Pubitemid 351958963)
60. Gaertner FC, Schwaiger M, Beer AJ: Molecular imaging of avb3 expression in cancer patients. Q. J. Nucl. Med. Mol. Imaging 54(3), 309-326 (2010).
61. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59(19), 5002-5011 (1999). (Pubitemid 29472907)
62. Bhowmick NA, Neilson EG, Moses HL: Stromal fibroblasts in cancer initiation and progression. Nature 432(7015), 332-337 (2004). (Pubitemid 39551661)
63. Orimo A, Weinberg RA: Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 5(15), 1597-1601 (2006). (Pubitemid 44285243)
64. Silzle T, Randolph GJ, Kreutz M, Kunz- Schughart LA: The fibroblast: sentinel cell and local immune modulator in tumor tissue. Int. J. Cancer 108(2), 173-180 (2004). (Pubitemid 37541767)
65. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121(3), 335-348 (2005). (Pubitemid 40692295)
66. Shao ZM, Nguyen M, Barsky SH: Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 19(38), 4337-4345 (2000).
67. Skobe M, Fusenig NE: Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc. Natl Acad. Sci. USA 95(3), 1050-1055 (1998). (Pubitemid 28124910)
68. Rofstad EK, Halsor EF: Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res. 60(17), 4932-4938 (2000).
69. Shao J, Sheng GG, Mifflin RC, Powell DW, Sheng H: Roles of myofibroblasts in prostaglandin E2-stimulated intestinal epithelial proliferation and angiogenesis. Cancer Res. 66(2), 846-855 (2006). (Pubitemid 43165950)
70. Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(d716) knockout mice. Nat. Med. 7(9), 1048-1051 (2001). (Pubitemid 32937386)
71. Seno H, Oshima M, Ishikawa TO, et al. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res. 62(2), 506-511 (2002). (Pubitemid 34110434)
72. Pozzi LA, Weiser WY: Human recombinant migration inhibitory factor activates human macrophages to kill tumor cells. Cell Immunol. 145(2), 372-379 (1992). (Pubitemid 23004550)
73. Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196(3), 254-265 (2002). (Pubitemid 34189413)
74. Zumsteg A, Christofori G: Corrupt policemen: inflammatory cells promote tumor angiogenesis. Curr. Opin. Oncol. 21(1), 60-70 (2009).
75. Lin EY, Nguyen AV, Russell RG, Pollard JW: Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193(6), 727-740 (2001).
76. Kalra VK, Shen Y, Sultana C, Rattan V: Hypoxia induces PECAM-1 phosphorylation and transendothelial migration of monocytes. Am. J. Physiol. 271(5 Pt 2), H2025-H2034 (1996).
77. Qian B, Deng Y, Im JH, et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 4(8), E6562 (2009).
78. Ojalvo LS, Whittaker CA, Condeelis JS, Pollard JW: Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J. Immunol. 184(2), 702-712 (2010).
79. Allavena P, Sica A, Solinas G, Porta C, Mantovani A: The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 66(1), 1-9 (2008). (Pubitemid 351324128)
80. Knowles H, Leek R, Harris AL: Macrophage infiltration and angiogenesis in hu-an malignancy. Novartis Found. Symp. 256, 189-200; discussion 200-184, 259-169 (2004).
81. Lin EY, Li JF, Bricard G, et al. Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol. Oncol. 1(3), 288-302 (2007). (Pubitemid 350181649)
82. Lin EY, Li JF, Gnatovskiy L, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 66(23), 11238-11246 (2006). (Pubitemid 46009952)
83. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, Schwendener RA: Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br. J. Cancer 95(3), 272-281 (2006). (Pubitemid 44187587)
84. Jin H, Su J, Garmy-Susini B, Kleeman J, Varner J: Integrin a4b1 promotes monocyte trafficking and angiogenesis in tumors. Cancer Res. 66(4), 2146-2152 (2006).
85. Polverini PJ: How the extracellular matrix and macrophages contribute to angiogenesis-dependent diseases. Eur. J. Cancer 32A(14), 2430-2437 (1996).
86. Sica A, Saccani A, Bottazzi B, et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-kB activation in tumor-associated macrophages. J. Immunol. 164(2), 762-767 (2000). (Pubitemid 30043699)
87. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C: Macrophages and angiogenesis. J. Leukoc. Biol. 55(3), 410-422 (1994). (Pubitemid 24097250)
88. Giraudo E, Inoue M, Hanahan D: An amino-bisphosphonate targets MMP-9- expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 114(5), 623-633 (2004). (Pubitemid 39578752)
89. Mira E, Lacalle RA, Buesa JM, et al. Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J. Cell Sci. 117(Pt 9), 1847-1857 (2004).
90. Lewis JS, Landers RJ, Underwood JC, Harris AL, Lewis CE: Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J. Pathol. 192(2), 150-158 (2000).
91. Leek RD, Landers RJ, Harris AL, Lewis CE: Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br. J. Cancer 79(5-6), 991-995 (1999). (Pubitemid 29082138)
92. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56(20), 4625-4629 (1996). (Pubitemid 26338061)
93. Allen M, Louise Jones J: Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J. Pathol. 223(2), 162-176 (2011).
94. Venneri MA, De Palma M, Ponzoni M, et al. Identification of proangiogenic Tie2- expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 109(12), 5276-5285 (2007). (Pubitemid 46890548)
95. Fiedler U, Scharpfenecker M, Koidl S, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 103(11), 4150-4156 (2004). (Pubitemid 38685356)
96. De Palma M, Venneri MA, Roca C, Naldini L: Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 9(6), 789-795 (2003). (Pubitemid 36749231)
97. Yang L, DeBusk LM, Fukuda K, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6(4), 409-421 (2004). (Pubitemid 39361441)
98. Pan PY, Wang GX, Yin B, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 111(1), 219-228 (2008).
99. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM: Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11(18), 6713-6721 (2005). (Pubitemid 41339014)
100. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H: STAT3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 118(10), 3367-3377 (2008).
101. Friedman AD: Transcriptional regulation of granulocyte and monocyte development. ncogene 21(21), 3377-3390 (2002). (Pubitemid 34587710)
102. Sandhu JK, Privora HF, Wenckebach G, Birnboim HC: Neutrophils, nitric oxide synthase, and mutations in the mutatect murine tumor model. Am. J. Pathol. 156(2), 509-518 (2000). (Pubitemid 30643806)
103. Clark RA, Klebanoff SJ: Neutrophil-mediated tumor cell cytotoxicity: role of the peroxidase system. J. Exp. Med. 141(6), 1442-1447 (1975).
104. Mueller MD, Lebovic DI, Garrett E, Taylor RN: Neutrophils infiltrating the endometrium express vascular endothelial growth factor: potential role in endometrial angiogenesis. Fertil. Steril. 74(1), 107-112 (2000). (Pubitemid 30427282)
105. Van Coillie E, Van Aelst I, Wuyts A, et al. Tumor angiogenesis induced by granulocyte chemotactic protein-2 as a countercurrent principle. Am. J. Pathol. 159(4), 1405-1414 (2001). (Pubitemid 32947970)
106. Nozawa H, Chiu C, Hanahan D: Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl Acad. Sci. USA 103(33), 12493-12498 (2006). (Pubitemid 44267286)
107. Coussens LM, Werb Z: Matrix metalloproteinases and the development of cancer. Chem. Biol. 3(11), 895-904 (1996). (Pubitemid 27017088)
108. Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP: Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc. Natl Acad. Sci. USA 104(51), 20262-20267 (2007).
109. McCourt M, Wang JH, Sookhai S, Redmond HP: Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch. Surg. 134(12), 1325-1331; discussion 1331-1322 (1999).
110. Cassatella MA: Neutrophil-derived proteins: selling cytokines by the pound. Adv. Immunol. 73, 369-509 (1999). (Pubitemid 29300434)
111. Scapini P, Nesi L, Morini M, et al. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J. Immunol. 168(11), 5798-5804 (2002). (Pubitemid 34556166)
112. Lawrence MB, Springer TA: Neutrophils roll on E-selectin. J. Immunol. 151(11), 6338-6346 (1993). (Pubitemid 23340380)
113. Pahler JC, Tazzyman S, Erez N, et al. Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 10(4), 329-340 (2008).
114. Tazi A, Bouchonnet F, Grandsaigne M, Boumsell L, Hance AJ, Soler P: Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. J. Clin. Invest. 91(2), 566-576 (1993). (Pubitemid 23064142)
115. Kataki A, Scheid P, Piet M, et al. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J. Lab. Clin. Med. 140(5), 320-328 (2002). (Pubitemid 35302024)
116. Mor F, Quintana FJ, Cohen IR: Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J. Immunol. 172(7), 4618-4623 (2004). (Pubitemid 38375280)
117. Dirkx AE, oude Egbrink MG, Wagstaff J, Griffioen AW: Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J. Leukoc. Biol. 80(6), 1183-1196 (2006). (Pubitemid 44904956)
118. von Tell D, Armulik A, Betsholtz C: Pericytes and vascular stability. Exp. Cell Res. 312(5), 623-629 (2006). (Pubitemid 43290338)
119. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the Tie2 receptor, during embryonic angiogenesis. Cell 87(7), 1171-1180 (1996). (Pubitemid 27010101)
120. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103(2), 159-165 (1999). (Pubitemid 29053133)
121. Jung YD, Ahmad SA, Liu W, et al. The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. Semin. Cancer Biol. 12(2), 105-112 (2002). (Pubitemid 34680739)
122. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 18(2), 338-340 (2004).
123. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D: Benefits of targeting both pericytes and endothelial cells in the tu-or vasculature with kinase inhibitors. J. Clin. Invest. 111(9), 1287-1295 (2003). (Pubitemid 36554699)
124. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64(11), 3731-3736 (2004). (Pubitemid 38697278)
125. Ozerdem U, Stallcup WB: Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan. Angiogenesis 7(3), 269-276 (2004).
126. Chantrain CF, Henriet P, Jodele S, et al. Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases. Eur. J. Cancer 42(3), 310-318 (2006). (Pubitemid 43132885)
127. Pupa SM, Menard S, Forti S, Tagliabue E: New insights into the role of extracellular matrix during tumor onset and progression. J. Cell Physiol. 192(3), 259-267 (2002). (Pubitemid 34827603)
128. Werb Z: ECM and cell surface proteolysis: regulating cellular ecology. Cell 91(4), 439-442 (1997). (Pubitemid 27508232)
129. Liotta LA, Kohn EC: The microenvironment of the tumour-host interface. Nature 411(6835), 375-379 (2001).
130. Nelson MR, Liew D, Bertram M, Vos T: Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70. BMJ 330(7503), 1306 (2005).
131. Serini G, Bochaton-Piallat ML, Ropraz P, et al. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-b1. J. Cell Biol. 142(3), 873-881 (1998). (Pubitemid 28381502)
132. Kaczmarek J, Castellani P, Nicolo G, Spina B, Allemanni G, Zardi L: Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int. J. Cancer 59(1), 11-16 (1994). (Pubitemid 24310940)
133. Castellani P, Borsi L, Carnemolla B, et al. Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am. J. Pathol. 161(5), 1695-1700 (2002). (Pubitemid 35265528)
134. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2(1), 38-47 (2002). (Pubitemid 37328806)
135. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1a in common human cancers and their metastases. Cancer Res. 59(22), 5830-5835 (1999).
136. Munoz-Najar UM, Neurath KM, Vumbaca F, Claffey KP: Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene 25(16), 2379-2392 (2006).
137. Semenza GL: Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3(10), 721-732 (2003). (Pubitemid 37328811)
138. Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109(9), 3812-3819 (2007). (Pubitemid 46641732)
139. Lardner A: The effects of extracellular pH on immune function. J. Leukoc. Biol. 69(4), 522-530 (2001). (Pubitemid 32294836)
140. Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1a is essential for myeloid cell-mediated inflammation. Cell 112(5), 645-657 (2003). (Pubitemid 36331777)
141. Murdoch C, Tazzyman S, Webster S, Lewis CE: Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J. Immunol. 178(11), 7405-7411 (2007). (Pubitemid 46847468)
142. Balkwill FR: Tumour necrosis factor and cancer. Prog. Growth Factor Res. 4(2), 121-137 (1992).
143. Kim Y, Lin Q, Glazer PM, Yun Z: Hypoxic tumor microenvironment and cancer cell differentiation. Curr. Mol. Med. 9(4), 425-434 (2009).
144. Farmer P, Bonnefoi H, Anderle P, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 15(1), 68-74 (2009).
145. Micke P, Ostman A: Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 45(Suppl. 2), S163-S175 (2004). (Pubitemid 39488186)
146. Joyce JA: Therapeutic targeting of the tumor microenvironment. Cancer Cell 7(6), 513-520 (2005). (Pubitemid 40799245)
147. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706), 58-62 (2005). (Pubitemid 40093472)
148. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of en-othelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165(1), 35-52 (2004).
149. Baluk P, Hashizume H, McDonald DM: Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 15(1), 102-111 (2005). (Pubitemid 40127638)
150. Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G: Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 5(4), 237-256 (2002). (Pubitemid 36875123)
151. Kerbel RS: Tumor angiogenesis. N. Engl. J. Med. 358(19), 2039-2049 (2008). (Pubitemid 351656458)
152. Ellis LM, Hicklin DJ: Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin. Cancer Res. 14(20), 6371-6375 (2008).
153. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004). (Pubitemid 38702844)
154. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357(26), 2666-2676 (2007).
155. Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J. Clin. Oncol. 25(13), 1651-1657 (2007) (Pubitemid 46797943)
156. Mulgrew K, Kinneer K, Yao XT, et al. Direct targeting of avb3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol. Cancer Ther. 5(12), 3122-3129 (2006).
157. Chatterjee S, Matsumura A, Schradermeier J, Gillespie GY: Human malignant glioma therapy using anti-avb3 integrin agents. J. Neurooncol. 46(2), 135-144 (2000). (Pubitemid 30352620)
158. Brown ER, Charles KA, Hoare SA, et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-a inhibitor, in patients with advanced cancer. Ann. Oncol. 19(7), 1340-1346 (2008). (Pubitemid 351911969)
159. Madhusudan S, Foster M, Muthuramalingam SR, et al. A Phase II study of etanercept (Enbrel), a tumor necrosis factor a inhibitor in patients with metastatic breast cancer. Clin. Cancer Res. 10(19), 6528-6534 (2004). (Pubitemid 39346547)
160. Hagemann T, Lawrence T, McNeish I, et al. ?Re-educating? tumor-associated macrophages by targeting NF-kB. J. Exp. Med. 205(6), 1261-1268 (2008). (Pubitemid 351831483)
161. Schon M, Wienrich BG, Kneitz S, et al. KINK-1, a novel small-molecule inhibitor of IKKb, and the susceptibility of melanoma cells to antitumoral treatment. J. Natl Cancer Inst. 100(12), 862-875 (2008). (Pubitemid 351881954)
162. Baron JA: Aspirin and NSAIDs for the prevention of colorectal cancer. Recent Results Cancer Res. 181, 223-229 (2009).
163. Bhatt RS, Merchan J, Parker R, et al. A Phase II pilot trial of low-dose, continuous infusion, or ?metronomic? paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer 116(7), 1751-1756 (2010).
164. Lipton A, Campbell-Baird C, Witters L, Harvey H, Ali S: Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. J. Clin. Gastroenterol. 44(4), 286-288 (2010).
165. Shojaei F, Ferrara N: Antiangiogenesis to treat cancer and intraocular neovascular disorders. Lab. Invest. 87(3), 227-230 (2007). (Pubitemid 46353946)
166. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)- inhibitor-resistant tumors without affecting healthy vessels. Cell 131(3), 463-475 (2007). (Pubitemid 350007692)
167. Lorusso G, Ruegg C: The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem. Cell Biol. 130(6), 1091-1103 (2008).